← ANALYST RATINGS · TIPRANKS
Parabilis Medicines, Inc. (PBLS): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $42.33, the highest $45.00, the lowest $40.00. The average is +86.1% from the last price of $22.75.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $28.00 → $24.50−12.5% | Hold | +7.7% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $28.00 → $24.00−14.3% | Sell | +5.5% | Downgrade | 15.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $28.00 → $25.00−10.7% | Hold | +9.9% | Reiterated | 15.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $28.00 → $24.50−12.5% | Sell | +7.7% | Downgrade | 15.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $28.00 → $24.50−12.5% | Sell | +7.7% | Downgrade | 15.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $24.50−15.5% | Sell | +7.7% | Downgrade | 15.10.26on TipRanks 03:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $45.00 | Buy | +97.8% | Reiterated | 16.09.26on TipRanks Sep 17 04:55 | +3.7%next day +9.7% · 5 days −11.8% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $40.00 | Buy | +75.8% | Reiterated | 14.08.26on TipRanks Aug 17 07:31 | +4.1%next day +0.9% · 5 days +7.5% | ↗ |
| Charles Zhu★★★★★★★★★★#351 · hits 64% · avg +25.8% | LifeSci Capital | $42.00 | Buy | +84.6% | Reiterated | 13.08.26on TipRanks 13:25 | −5.3%next day +4.1% · 5 days +12.9% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $40.00 | Buy | +75.8% | Initiated | 06.07.26on TipRanks 11:15 | −2.2%next day +4.4% · 5 days +1.8% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Initiated | 06.07.26on TipRanks 07:55 | −2.2%next day +4.4% · 5 days +1.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Parabilis Medicines, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $41.75 at a price of $32.29 (+29.3%); now: $42.33 at $22.75 (+86.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 6 | 9 | 10 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Parabilis Medicines, Inc.
- CEO: Mathai Mammen
- Employees: 145
- 30 Acorn Park Dr, Cambridge, MA, 02140, US
- www.parabilismed.com
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
Data from the stock’s TipRanks forecast page, read 222 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗